Signet ring cell carcinoma
MONDO:0005092A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.
Also known as: signet ring carcinoma NOS (morphologic abnormality), signet ring cell adenocarcinoma, signet ring cell carcinoma, signet ring cell carcinoma (morphologic abnormality)
2750 clinical trials for this condition and its sub-types, 4 tagged with Signet ring cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Signet ring cell carcinoma
-
Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types
2 sub-types
-
Krukenberg carcinoma 1 trial
-
Lung signet ring cell carcinoma 1 trial
-
2 sub-types
-
Signet ring cell breast carcinoma 0 trials
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo aims to outsmart stubborn colorectal cancer
Disease control OngoingThis phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well…
Phase 2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC